AstraZeneca's Tezepelumab (thymic stromal lymphopoietin antagonist) Receives FDA BT Designation for the Treatment of Severe Asthma with irrespective T2 biomarker status
Shots:
- The designation is based on P-IIb PATHWAY assessing (tezepelumab vs PBO) in patients with asthma exacerbations- uncontrolled asthma receiving inhaled corticosteroids/LA- β2-agonists w/o oral corticosteroids and additional asthma controllers
- P-IIb PATHWAY involves administering of (70/210mg q4w or 280mg q2w) which showed reduction in annual asthma exacerbation rate reductions of 62%- 71% and 66% vs PBO
- AZ received seven BT designation since 2014- with first in respiratory and tezepelumab is under P-III PATHFINDER clinical trial programme
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
